The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 10, Issue , 2018, Pages 130-142

  Johnson, Sterling C ^a,b   Koscik, Rebecca L ^a   Jonaitis, Erin M ^a   Clark, Lindsay R ^a,b   Mueller, Kimberly D ^a   Berman, Sara E ^a   Bendlin, Barbara B ^a   Engelman, Corinne D ^a   Okonkwo, Ozioma C ^a   Hogan, Kirk J ^a   Asthana, Sanjay ^a,b   Carlsson, Cynthia M ^a,b   Hermann, Bruce P ^a   Sager, Mark A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Biomarkers; Preclinical Alzheimer's disease; Risk factors

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN E4; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIET; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HUMAN; LIFESTYLE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MOOD; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; REVIEW; SELF REPORT; SLEEP;

EID: 85039984735     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2017.11.007     Document Type: Review

References (100)

1. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
2. Sager, M.A., Hermann, B., La Rue, A., Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 18 (2005), 245–249.
3. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
4. Ellis, R.J., Jan, K., Kawas, C., Koller, W.C., Lyons, K.E., Jeste, D.V., et al. Diagnostic validity of the dementia questionnaire for Alzheimer disease. Arch Neurol 55 (1998), 360–365.
5. Kawas, C., Segal, J., Stewart, W.F., Corrada, M., Thal, L.J., A validation study of the Dementia Questionnaire. Arch Neurol 51 (1994), 901–906.
6. Wechsler, D., WASI: Wechsler Abbreviated Scale of Intelligence. 1999, The Psychological Corporation, San Antonio, TX.
7. Wilkinson, G.S., The Wide Range Achievement Test: Manual. 3rd ed., 1993, Jastak Association, Wilmington, DE.
8. Schmidt, M., Rey Auditory Verbal Learning Test: A Handbook. 1996, Western Psychological Services, Los Angeles, CA.
9. Kaplan, E., Goodglass, H., Weintraub, S., Boston Naming Test – Second Edition. 2001, PRO-ED, Inc, Austin, TX.
10. Rouleau, I., Salmon, D.P., Butters, N., Kennedy, C., McGuire, K., Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 18 (1992), 70–87.
11. Benton, A.L., Hamsher, K.S., Sivan, A.B., Multilingual Aphasia Examination. 1994, Psychological Assessment Resources, Lutz, FL.
12. Wechsler, D., Wechsler Adult Intelligence Scale–III. 1997, The Psychological Corporation, San Antonio, TX.
13. Reitan, R.M., Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual Mot Skills 8 (1958), 271–276.
14. Trenerry, M.R., Crosson, B., DeBoe, J., Leber, W.R., The Stroop Neuropsychological Screening Test. 1989, Pychological Assessment Resources, Inc, Odessa, FL.
15. Benedict, R.H., Brief Visuospatial Memory Test–Revised. 1997, Psychological Assessment Resources, Inc, Odessa, FL.
16. Wechsler, D., Wechsler Adult Intelligence Scale–Revised. 1981, Harcourt Brace & Co. for The Psychological Corporation, San Antonio, TX.
17. Wechsler, D., Wechsler Memory Scale–Revised. 1987, Harcourt Brace Jovanovich, Inc. for the Psychological Corporation, New York, NY.
18. Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
19. Rosen, W.G., Verbal fluency in aging and dementia. J Clin Exp Neuropsychol 2 (1980), 135–146.
20. Goodglass, H., Kaplan, E., Boston Diagnostic Aphasia Examination–3rd Edition. 1983, Lippincott Williams & Wilkins, Baltimore, MD.
21. Cogstate. Cogstate Research Manual, Version 6. 2011, Cogstate, Melbourne, Australia.
22. Radloff, L.S., The CES-D Scale. Appl Psychol Meas 1 (1977), 385–401.
23. Morris, M.C., Tangney, C.C., Wang, Y., Sacks, F.M., Barnes, L.L., Bennett, D.A., et al. MIND diet slows cognitive decline with aging. Alzheimers Dement 11 (2015), 1015–1022.
24. Stewart, A.L., Mills, K.M., King, A.C., Haskell, W.L., Gillis, D., Ritter, P.L., CHAMPS physical activity questionnaire for older adults: outcomes for interventions. Med Sci Sports Exerc 33 (2001), 1126–1141.
25. Hays, R.D., Stewart, A.L., Sleep measures. Stewart, A.L., Ware, J.E., (eds.) Measuring function and well-being, 1992, Duke University Press, Durham.
26. Johns, M.W., A new method for measuring daytime sleepiness: the Epworth sleepiness scale. sleep 14 (1991), 540–545.
27. Bastien, C.H., Vallières, A., Morin, C.M., Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2 (2001), 297–307.
28. Schinka, J.A., Mcbride, A., Vanderploeg, R.D., Tennyson, K., Borenstein, A.R., Mortimer, J.A., Florida cognitive activities scale: initial development and validation. J Int Neuropsychol Soc 11 (2005), 108–116.
29. Galvin, J.E., The Quick Dementia Rating System (Qdrs): a rapid dementia staging tool. Alzheimers Dement (Amst) 1 (2015), 249–259.
30. Morris, J.C., Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int psychogeriatrics 9 (1997), 173–176.
31. Jorm, A., Jacomb, P., The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 19 (1989), 1015–1022.
32. Lawton, M.P., Brody, E.M., Assessment of older people: self-maintaining and instrumental activities of daily living. Nurse Res, 19, 1970, 278.
33. Berman, S.E., Koscik, R.L., Clark, L.R., Mueller, K.D., Bluder, L., Galvin, J.E., et al. Use of the Quick Dementia Rating System (QDRS) as an initial screening measure in a longitudinal cohort at risk for Alzheimer's disease. JAD Rep 1 (2017), 9–13.
34. Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
35. Edmonds, E.C., Delano-Wood, L., Clark, L.R., Jak, A.J., Nation, D.A., McDonald, C.R., et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement 11 (2015), 415–424.
36. Pedraza, O., Lucas, J.A., Smith, G.E., Petersen, R.C., Graff-Radford, N.R., Ivnik, R.J., Robust and expanded norms for the Dementia Rating Scale. Arch Clin Neuropsychol 25 (2010), 347–358.
37. Sliwinski, M., Lipton, R.B., Buschke, H., Stewart, W., The effects of preclinical dementia on estimates of normal cognitive functioning in aging. J Gerontol B Psychol Sci Soc Sci 51 (1996), 217–225.
38. De Santi, S., Pirraglia, E., Barr, W., Babb, J., Williams, S., Rogers, K., et al. Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. Neuropsychology 22 (2008), 469–484.
39. Koscik, R.L., La Rue, A., Jonaitis, E.M., Okonkwo, O.C., Johnson, S.C., Bendlin, B.B., et al. Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer's prevention. Dement Geriatr Cogn Disord 38 (2014), 16–30.
40. Clark, L.R., Koscik, R.L., Nicholas, C.R., Okonkwo, O.C., Engelman, C.D., Bratzke, L.C., et al. Mild cognitive impairment in late middle age in the Wisconsin Registry for Alzheimer's Prevention Study: prevalence and characteristics using robust and standard neuropsychological normative data. Arch Clin Neuropsychol 31 (2016), 675–688.
41. Koscik, R.L., Berman, S.E., Clark, L.R., Mueller, K.D., Okonkwo, O.C., Gleason, C.E., et al. Intraindividual cognitive variability in middle age predicts cognitive impairment 8-10 years later: results from the Wisconsin Registry for Alzheimer's Prevention. J Int Neuropsychol Soc 22 (2016), 1016–1025.
42. Jack CRJ, Bennett DA, Blennow K, Carrillo MC, Dunn B, Elliott C, et al. NIA-AA research framework: towards a biological definition of Alzheimer's disease. Available at: https://www.alz.org/aaic/nia-aa.asp. Accessed December 22, 2017.
43. Bendlin, B.B., Carlsson, C.M., Johnson, S.C., Zetterberg, H., Blennow, K., Willette, A.A., et al. CSF T-Tau/Abeta42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One, 7, 2012, e37720.
44. Racine, A.M., Koscik, R.L., Berman, S.E., Nicholas, C.R., Clark, L.R., Okonkwo, O.C., et al. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain 139 (2016), 2261–2274.
45. Racine, A.M., Koscik, R.L., Nicholas, C.R., Clark, L.R., Okonkwo, O.C., Oh, J.M., et al. Cerebrospinal fluid ratios with Abeta42 predict preclinical brain beta-amyloid accumulation. Alzheimers Dement (Amst) 2 (2016), 27–38.
46. Sprecher, K.E., Koscik, R.L., Carlsson, C.M., Zetterberg, H., Blennow, K., Okonkwo, O.C., et al. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 89 (2017), 445–453.
47. Dean, D.C. 3rd, Hurley, S.A., Kecskemeti, S.R., O'Grady, J.P., Canda, C., Davenport-Sis, N.J., et al. Association of amyloid pathology with myelin alteration in preclinical Alzheimer disease. JAMA Neurol 74 (2017), 41–49.
48. Hoy, A.R., Ly, M., Carlsson, C.M., Okonkwo, O.C., Zetterberg, H., Blennow, K., et al. Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging. PLoS One, 12, 2017, e0173982.
49. Almeida, R.P., Schultz, S.A., Austin, B.P., Boots, E.A., Dowling, N.M., Gleason, C.E., et al. Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease. JAMA Neurol 72 (2015), 699–706.
50. Schultz, S.A., Boots, E.A., Darst, B.F., Zetterberg, H., Blennow, K., Edwards, D.F., et al. Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. Neurology 88 (2017), 1650–1658.
51. Johnson, S.C., Christian, B.T., Okonkwo, O.C., Oh, J.M., Harding, S., Xu, G., et al. Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging 35 (2014), 576–584.
52. Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 (2013), 1452–1458.
53. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. TREM2 variants in Alzheimer's disease. N Engl J Med 368 (2013), 117–127.
54. Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368 (2013), 107–116.
55. Cruchaga, C., Karch, C.M., Jin, S.C., Benitez, B.A., Cai, Y., Guerreiro, R., et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 505 (2014), 550–554.
56. Darst, B.F., Koscik, R.L., Racine, A.M., Oh, J.M., Krause, R.A., Carlsson, C.M., et al. Pathway-specific polygenic risk scores as predictors of amyloid-beta deposition and cognitive function in a sample at increased risk for Alzheimer's disease. J Alzheimers Dis 55 (2017), 473–484.
57. Dowling, N.M., Hermann, B., La Rue, A., Sager, M.A., Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology 24 (2010), 742–756.
58. Mueller, K.D., Koscik, R.L., Turkstra, L.S., Riedeman, S.K., LaRue, A., Clark, L.R., et al. Connected language in late middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis 54 (2016), 1539–1550.
59. Mueller, K.D., Koscik, R.L., LaRue, A., Clark, L.R., Hermann, B., Johnson, S.C., et al. Verbal fluency and early memory decline: results from the Wisconsin Registry for Alzheimer's Prevention. Arch Clin Neuropsychol 30 (2015), 448–457.
60. Bondi, M.W., Edmonds, E.C., Jak, A.J., Clark, L.R., Delano-Wood, L., McDonald, C.R., et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis 42 (2014), 275–289.
61. Clark, L.R., Delano-Wood, L., Libon, D.J., McDonald, C.R., Nation, D.A., Bangen, K.J., et al. Are empirically-derived subtypes of mild cognitive impairment consistent with conventional subtypes?. J Int Neuropsychol Soc 19 (2013), 635–645.
62. La Rue, A., Hermann, B., Jones, J.E., Johnson, S., Asthana, S., Sager, M.A., Effect of parental family history of Alzheimer's disease on serial position profiles. Alzheimers Dement 4 (2008), 285–290.
63. Engelman, C.D., Koscik, R.L., Jonaitis, E.M., Hermann, B.P., La Rue, A., Sager, M.A., Investigation of triggering receptor expressed on myeloid cells 2 variant in the Wisconsin Registry for Alzheimer's Prevention. Neurobiol Aging 35 (2014), 1252–1254.
64. Engelman, C.D., Koscik, R.L., Jonaitis, E.M., Okonkwo, O.C., Hermann, B.P., La Rue, A., et al. Interaction between two cholesterol metabolism genes influences memory: findings from the Wisconsin Registry for Alzheimer's Prevention. J Alzheimers Dis 36 (2013), 749–757.
65. Boots, E.A., Schultz, S.A., Clark, L.R., Racine, A.M., Darst, B.F., Koscik, R.L., et al. BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention. Neurology 88 (2017), 2098–2106.
66. Laird, N.M., Ware, J.H., Random-effects models for longitudinal data. Biometrics 38 (1982), 963–974.
67. Singer, J.D., Using SAS PROC MIXED to fit multilevel models, hierarchical models and individual growth models. J Educ Behav Stat 24 (1998), 323–355.
68. Jonaitis, E.M., Koscik, R.L., La Rue, A., Johnson, S.C., Hermann, B.P., Sager, M.A., Aging, practice effects, and genetic risk in the Wisconsin Registry for Alzheimer's Prevention. Clin Neuropsychol 29 (2015), 426–441.
69. Clark, L.R., Berman, S.E., Norton, D., Koscik, R.L., Jonaitis, E.M., Blennow, K., et al. Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid. bioRxiv, 2017, 10.1101/220756 [E-pub ahead of print].
70. Jack, C.R. Jr., Bennett, D.A., Blennow, K., Carrillo, M.C., Feldman, H.H., Frisoni, G.B., et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87 (2016), 539–547.
71. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
72. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004), 306–319.
73. Blennow, K., Dubois, B., Fagan, A.M., Lewczuk, P., de Leon, M.J., Hampel, H., Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11 (2015), 58–69.
74. Johnson, S.C., Ries, M.L., Hess, T.M., Carlsson, C.M., Gleason, C.E., Alexander, A.L., et al. Effect of Alzheimer disease risk on brain function during self-appraisal in healthy middle-aged adults. Arch Gen Psychiatry 64 (2007), 1163–1171.
75. Johnson, S.C., Schmitz, T.W., Trivedi, M.A., Ries, M.L., Torgerson, B.M., Carlsson, C.M., et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci 26 (2006), 6069–6076.
76. Xu, G., McLaren, D.G., Ries, M.L., Fitzgerald, M.E., Bendlin, B.B., Rowley, H.A., et al. The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain 132 (2009), 383–391.
77. Bendlin, B.B., Ries, M.L., Canu, E., Sodhi, A., Lazar, M., Alexander, A.L., et al. White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement 6 (2010), 394–403.
78. Okonkwo, O.C., Xu, G., Dowling, N.M., Bendlin, B.B., Larue, A., Hermann, B.P., et al. Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. Neurology 78 (2012), 1769–1776.
79. Clark, L.R., Racine, A.M., Koscik, R.L., Okonkwo, O.C., Engelman, C.D., Carlsson, C.M., et al. Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement 12 (2016), 805–814.
80. Boots, E.A., Schultz, S.A., Almeida, R.P., Oh, J.M., Koscik, R.L., Dowling, M.N., et al. Occupational complexity and cognitive reserve in a middle-aged cohort at risk for Alzheimer's disease. Arch Clin Neuropsychol 30 (2015), 634–642.
81. Schultz, S.A., Larson, J., Oh, J., Koscik, R., Dowling, M.N., Gallagher, C.L., et al. Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease. Brain Imaging Behav 9 (2015), 729–736.
82. Jonaitis, E.M., La Rue, A., Mueller, K.D., Koscik, R.L., Hermann, B., Sager, M.A., Cognitive activities and cognitive performance in middle-aged adults at risk for Alzheimer's disease. Psychol Aging 28 (2013), 1004–1014.
83. Zuelsdorff, M.L., Koscik, R.L., Okonkwo, O.C., Peppard, P.E., Hermann, B.P., Sager, M.A., et al. Reliability of a Novel Social Activity Questionnaire. J Aging Health, 2016, 10.1177/0898264316674812 [Epub ahead of print].
84. Zuelsdorff, M.L., Engelman, C.D., Friedman, E.M., Koscik, R.L., Jonaitis, E.M., Rue, A.L., et al. Stressful events, social support, and cognitive function in middle-aged adults with a family history of Alzheimer's disease. J Aging Health 25 (2013), 944–959.
85. Sprecher, K.E., Bendlin, B.B., Racine, A.M., Okonkwo, O.C., Christian, B.T., Koscik, R.L., et al. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging 36 (2015), 2568–2576.
86. Ward, M.A., Bendlin, B.B., McLaren, D.G., Hess, T.M., Gallagher, C.L., Kastman, E.K., et al. Low HDL cholesterol is associated with lower gray matter volume in cognitively healthy adults. Front Aging Neurosci, 2, 2010, 10.3389/fnagi.2010.00029.
87. Willette, A.A., Xu, G., Johnson, S.C., Birdsill, A.C., Jonaitis, E.M., Sager, M.A., et al. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes care 36 (2013), 443–449.
88. Birdsill, A.C., Carlsson, C.M., Willette, A.A., Okonkwo, O.C., Johnson, S.C., Xu, G., et al. Low cerebral blood flow is associated with lower memory function in metabolic syndrome. Obesity 21 (2013), 1313–1320.
89. Starks, E.J., Patrick O'Grady, J., Hoscheidt, S.M., Racine, A.M., Carlsson, C.M., Zetterberg, H., et al. Insulin resistance is associated with higher cerebrospinal fluid tau levels in asymptomatic APOEvarepsilon4 carriers. J Alzheimers Dis 46 (2015), 525–533.
90. Willette, A.A., Bendlin, B.B., Starks, E.J., Birdsill, A.C., Johnson, S.C., Christian, B.T., et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol 72 (2015), 1013–1020.
91. Willette, A.A., Johnson, S.C., Birdsill, A.C., Sager, M.A., Christian, B., Baker, L.D., et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 11 (2015), 504–510.e1.
92. Barnes, D.E., Yaffe, K., The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10 (2011), 819–828.
93. Sabia, S., Dugravot, A., Dartigues, J.F., Abell, J., Elbaz, A., Kivimaki, M., et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ, 357, 2017, j2709.
94. Boots, E.A., Schultz, S.A., Oh, J.M., Larson, J., Edwards, D., Cook, D., et al. Cardiorespiratory fitness is associated with brain structure, cognition, and mood in a middle-aged cohort at risk for Alzheimer's disease. Brain Imaging Behav 9 (2015), 639–649.
95. Dougherty, R.J., Ellingson, L.D., Schultz, S.A., Boots, E.A., Meyer, J.D., Lindheimer, J.B., et al. Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease. Alzheimers Dement (Amst) 4 (2016), 14–17.
96. Okonkwo, O.C., Schultz, S.A., Oh, J.M., Larson, J., Edwards, D., Cook, D., et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 83 (2014), 1753–1760.
97. Dougherty, R.J., Schultz, S.A., Kirby, T.K., Boots, E.A., Oh, J.M., Edwards, D., et al. Moderate physical activity is associated with cerebral glucose metabolism in adults at risk for Alzheimer's disease. J Alzheimers Dis 58 (2017), 1089–1097.
98. Bilgel, M., Koscik, R.L., An, Y., Prince, J.L., Resnick, S.M., Johnson, S.C., et al. Temporal order of Alzheimer's disease-related cognitive marker changes in BLSA and WRAP longitudinal studies. J Alzheimers Dis 59 (2017), 1335–1347.
99. Neu, S.C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol 74 (2017), 1178–1189.
100. Gross, A.L., Hassenstab, J.J., Johnson, S.C., Clark, L.R., Resnick, S.M., Kitner-Triolo, M., et al. A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: the preclinical AD consortium. Alzheimers Dement (Amst) 8 (2017), 147–155.